Fulgent Genetics (FLGT) Receivables - Net (2015 - 2026)

Fulgent Genetics has disclosed Receivables - Net across 12 years of filings, most recently posting $64.9 million for Q2 2026.

• In Q2 2026, Receivables - Net fell 15.87% year-over-year to $64.9 million; the TTM figure through Jun 2026 stood at $64.9 million (down 15.87% YoY), while the FY2025 annual figure was $84.8 million, up 22.81% from the prior year.
• Receivables - Net came in at $64.9 million for Q2 2026 at Fulgent Genetics, down from $69.3 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $160.3 million in Q1 2022 to a low of $93000.0 in Q4 2022.
• Average Receivables - Net over 5 years is $69.5 million, with a median of $67.0 million recorded in 2024.
• Year-over-year, Receivables - Net sank 99.93% in 2022 and jumped 54880.65% in 2023.
• Over 5 years, Receivables - Net stood at $93000.0 in 2022, then jumped by 54880.65% to $51.1 million in 2023, then jumped by 34.99% to $69.0 million in 2024, then grew by 22.81% to $84.8 million in 2025, then fell by 23.39% to $64.9 million in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $64.9 million in Q2 2026, $69.3 million in Q1 2026, and $84.8 million in Q4 2025.